|
|
|
1081: Magnetic Resonance Lymphography with Ferumoxtran-10 for Pelvic Lymph Node Target Delineation in Bladder and Prostate Cancer
|
Dinniwell, Robert |
|
1082: IMRT Improves Pelvic Lymph Node (PLN) Coverage and Dose to Critical Structures Compared with Standard Four Field (4F) Whole Pelvis (WP) Radiation Therapy (RT) in Prostate Cancer (PC)
|
Wang-Chesebro, Alice |
|
1083: The Clinical Impact of Local Radiation Therapy and the Percentage of Positive Lymph Nodes in Prostate Cancer PatientsTreated with Hormonal Therapy
|
Lee, Andrew |
|
1084: Real Time Prostate Translation, Rotation, Deformation Evaluated with Calypso Beacon
|
Burch, Douglas |
|
1085: Intra-Fraction Prostate Motion Using MV Fluoroscopy
|
Lometti, Michael |
|
1086: Ultrasound vs. Seed Marker Prostate Localization
|
Scarbrough, Todd |
|
1087: Clinical Experience With The Calypso
|
Kupelian, Patrick |
|
1088: Assessing the Utility of a 2-Year Post Treatment Biopsy for Forecasting Eventual Biochemical Failure and Survival
|
Vance, Waseet |
|
1089: How Reliable are Electronic Biochemical Failure Algorithms? An Examination of the Variability of Results from Four Centers
|
Williams, Scott |
|
1090: Changing Definitions of Biochemical Failure after External Beam Radiotherapy for Localized Prostate Cancer: Effect on Outcome Analyses
|
Reddy, Chandana |
|
1091: First Year PSA Kinetics and Nadirs after Prostate Cancer Radiotherapy are Predictive of Overall Survival
|
Cheung, Rex |
|
1092: The Percentage of Positive Cores is not an Appropriate Risk Factor for Prostate Radiotherapy to
|
Buyyounouski, Mark |
|
1093: Dosimetric Quantifiers for Low Dose Rate Prostate Brachytherapy: V100 is Superior to D90
|
Papagikos, Michael |
|
2096: Bicalutamide 150 mg in Addition to Standard Care Delays Progression to Bone Metastases in Patients with LocallyAdvanced Prostate Cancer: Analyses from the Second Analysis of the Early Prostate Cancer Program
|
See, William |
|
2097: Predictors of Rectal Acute Toxicity in High-Dose 3D-CRT for Prostate Cancer. Results from a Prospective Multi-Centric Study Performed by the AIRO National Working Group on Prostate Irradiation
|
Valdagni, Riccardo |
|
2098: Adjuvant Androgen Deprivation Therapy Offers a "CURE" in Patients with Poor Prognosis Non-Metastatic Prostate Cancer
|
Fleshner, Neil |
|
2099: 20 Gy versus 44 Gy Supplemental Beam Radiation with Pd-103 Prostate Brachytherapy: Early Biochemical Outcomes froma Prospective Randomized Multi-Center Trial
|
Orio, Peter |
|
2100: Biochemical Relapse-Free Survival After High Dose External Radiotherapy (
|
Reuther, Alwyn |
|
2101: Late Toxicity and Early Prostate-Specific Antigen Outcome Following Salvage Prostate Brachytherapy For Select PatientsFollowing Primary Radiation Therapy
|
Suh, W. Warren |
|
2102: Salvage Prostate Brachytherapy Following Radiotherapy Failure
|
Lo, Kathy |
|
2103: Comparison of Two Fractionation Schedules for Conformal Radiation Therapy for Prostate Cancer
|
Mahadevan, Arul |
|
2104: Prostate Specific Antigen Half-Life Following Salvage Radiation Therapy for an Isolated PSA Elevation After Radical Prostatectomy
|
Buskirk, Steven |
|
2105: Biologically Effective Dose Values for Prostate Brachytherapy: Effects on PSA Failure and Post-Treatment Biopsy Results
|
Stock, Richard |
|
2106: Preoperative PSA Velocity Predicts for Relapse after Radical Prostatectomy
|
King, Christopher |
|
2107: Increased Risk of Biochemical and Local Failure in Patients with Distended Rectum on the Planning CT for Prostate Cancer Radiotherapy
|
de Crevoisier, Renaud |
|
2108: Dose-Volume Determinants of Late Genitourinary Toxicity after External Beam Radiotherapy for Prostate Cancer
|
Alcantara, Pino |
|
2109: VEGF-D Expression Predicts Biochemical Outcome in Localized Prostate Cancer Treated with External Radiation: a Ten Year Cohort Analysis
|
Bermudez, Scott |
|
2110: Analysis of Biochemical Failure Definitions Based on Absolute and Current Nadir Methodologies and Their Integration with Prostate-Specific Antigen (PSA) Doubling Time
|
Kestin, Larry |
|
2111: Predictors of Hormone Refractory Disease in Men Treated with Salvage Androgen Deprivation following Definitive Radiotherapy for Prostate Cancer
|
Hanlon, Alexandra |
|
2112: Iodine 125 Brachytherapy for Favorable Risk Prostate Cancer: Results for 509 Patients. When Can We Start to Trust PSA after Brachytherapy?
|
Crook, Juanita |
|
2113: Phase II Trial of External Radiotherapy, Brachytherapy, Androgen Deprivation and Docetaxel Chemotherapy for High-Risk, Localized Prostate Cancer
|
DiBiase, Steven |
|
2114: Match Pair Analysis of Prostate Cancer Patients at risk of Positive Pelvic Lymph Nodes >15% Treated to High Radiation Doses With and Without Pelvic EBRT
|
Boike, Thomas |
|
2115: Long-term Prostate Cancer Control (13 Year Actuarial) in Patients with a High Likelihood of Extracapsular Cancer Extension Using PD-103 Brachytherapy and Supplemental Beam Radiation
|
Dattoli, Michael |
|
2116: Prostate Brachytherapy In Twenty-Four Patients With Inflammatory Bowel Disease
|
Peters, Christopher |
|
2117: Efficacy Of Neoadjuvant Dutasteride And Bicalutamide As A Cytoreductive Regimen Prior To Permanent Interstitial Brachytherapy
|
Anderson, Richard |
|
2118: Prostate Brachytherapy-Induced Urethral Strictures
|
Butler, Wayne |
|
2119: Sustained Long-term Immune Responses Following In Situ Gene Therapy Combined with Radiotherapy and Hormonal Therapy in Prostate Cancer Patients
|
Fujita, Tetsuo |
|
2120: Defining the Rectal Dose Constraint for Permanent Radioactive Seed Implantation of the Prostate
|
Albert, Michele |
|
2121: Percent Positive Cores and Proportion Cancer Volume as Prognostic Factors for Prostate Radiation Therapy
|
Ray, Michael |
|
2122: Clinical Implication of PSA Bounce after Treatment of Prostate Cancer with Brachytherapy and/or External Beam Radiotherapy with or without Androgen Deprivation
|
Antonucci, J |
|
2123: Intraprostatic Fiducials for Localization of the Prostate Gland: Monitoring Intermarker Distances During Radiation Therapy to Test for Marker Stability
|
Maach, Mourad |
|
2124: Time Course of Recovery of Serum Testosterone following Short Course Neo Adjuvant LHRH Analogue and Radical Radiotherapy in Localised Prostate Cancer
|
Murthy, Vedang |
|
2125: Combined Prostate Brachytherapy and Short-Term Androgen Deprivation Therapy as Salvage Treatment for Patients with Locally Recurrent Prostate Cancer after External Beam Irradiation
|
Wong, William |
|
2126: Outcome Assessment Using Hazard Ratios for Intermediate and High Risk Prostate Cancer Patients Treated with Accelerated Hypofractionated High Dose Radiation without Androgen Deprivation
|
Galalae, Razvan |
|
2127: Interstitial High Dose Rate (HDR) Brachytherapy for Early Stage Prostate Cancer
|
Mark, Rufus |
|
2128: Daily Electronic Portal Imaging of Implanted Gold Seed Fiducials in Patients Undergoing Salvage Radiotherapy After Radical Prostatectomy
|
Schiffner, Daniel |
|
2129: Study of Lymphatic Drainage by SPECT-CT Fusion Images for Pelvic Irradiation of Prostate Cancer
|
Krengli, Marco |
|
2130: Interim Results of a Phase II Dose Escalating Trial with Image Guided Adaptive Radiotherapy for the Treatment of Early toHigh Risk Prostate Cancer Patients: Improved Outcome with Increased EBRT Doses
|
Martinez, Alvaro |
|
2131: Salvage Brachytherapy for the Prostate: Correlation of MR/MRS Imaging and the Pre-Salvage Biopsy for Locally Recurrent Carcinoma of the Prostate
|
Wallace, Timothy |
|
2132: Prostate Position Variability and Dose-Volume-Histograms in Radiotherapy for Prostate Cancer with Full and Empty Bladder
|
Pinkawa, Michael |
|
2133: Adaptive Radiotherapy for Invasive Bladder Cancer, a Feasibility Study
|
Pos, Floris |
|
2134: Comparison of the ASTRO Consensus Definition versus the Houston/Current PSA Nadir + 2 Definition of Biochemical Failure in Prostate Cancer Patients Undergoing Permanent Iodine-125 Brachytherapy
|
Linstadt, David |
|
2135: Daily Megavoltage CT Imaging in Patients with Prostate Cancer Receiving Postoperative Radiation Therapy: Does the Prostate Bed Move?
|
Burkavage, Robert |
|
2136: Daily Dose Recalculation using Megavoltage CT Images During Tomotherapy for Localized Prostate Cancer: Dosimetric Analysis for the Prostate Gland, Rectum and Bladder for the Full Treatment Course
|
Zeidan, Omar |
|
2137: Defining Biochemical Control after Prostate Brachytherapy: Can We Use a Target PSA?
|
Coen, John |
|
2138: Debulking Prostatectomy for cT4 Prostate Cancer: Role of Adjuvant Therapy
|
Johnstone, Peter |
|
2139: Men with Intermediate Risk Prostate Cancer with a History of Transurethral Resection of Prostate (TURP) have a Higher Risk of Biochemical Failure
|
D'Ambrosio, David |
|
2140: The Relationship of International Prostate Symptom Score with Urinary Flow Studies, and Catheterization Rates following Iodine 125 Prostate Brachytherapy
|
Martens, Chandra |
|
2141: A Phase II Study of Imatinib Mesylate In Prostate Cancer Patients With Evidence of Biochemical Relapse Following Definitive Radical Retropubic Prostatectomy or Radiation Therapy
|
Bajaj, Gopal |
|
2142: IMRT versus Conventional Whole Pelvis Radiotherapy for Prostate Cancer: Planning Comparison and Analysis of Acute Toxicity
|
Su, Andy |
|
2143: Interstitial High Dose Rate (HDR) Brachytherapy + IMRT vs. HDR Monotherapy for Early Stage Prostate Cancer
|
Neumann, Thomas |
|
2144: Role of Pelvic Lymphadenectomy (PL) and Adjuvant Androgent Deprivation (AAD) in Patients Treated with Radical Prostatectomy (RP) and Early Adjuvant RT (EART): Results of a Multi-Institutional, Retrospective, Italian Study on 681Cases
|
Cozzarini, C |
|
2145: Proctitis after 3D-Conformal Radiotherapy of Localized Prostate Cancer: Classification According to the Vienna Rectoscopy Score and Correlation to the EORTC/RTOG Score within the Austrian-German Multicenter Prostate Cancer Trial
|
Goldner, Gregor |
|
2146: High Dose Rate Monotherapy for Prostate Cancer
|
Schour, Lionel |
|
2147: Treatment of Localized Prostate Cancer with External Beam Radiation Therapy and High Dose Rate Interstitial Brachytherapy
|
Phan, Thinh |
|
2148: Improved Understanding of Subtle Rectal Toxicity after Prostate Brachytherapy: Results with a Comprehensive ToxicityScoring System and Identification of Rectal Dosimetric Toxicity Predictors
|
Shah, Jinesh |
|
2149: I-125 Versus Pd-103 for Low Risk Prostate Cancer: Morbidity Outcomes from a Prospective Randomized Multi-Center Controlled Trial
|
Herstein, Andrew |
|
2150: PSA Kinetics following Prostate Brachytherapy: The PSA Bounce Phenomenon and Its Implications for PSA Doubling Time
|
Ciezki, Jay |
|
2151: External Beam Radiation Dose Response and Toxicity in Low-Risk Prostate Cancer
|
Anderson, Carryn |
|
2152: Phospho-AKT Expression and Prognosis of Locally Advanced Prostate Cancer: A Study Based on RTOG 8610
|
Zhai, G. |
|
2153: First Report on the Clinical Use of Palladium-103 Coils: Safety and Efficacy in the Brachytherapy Treatment of Early Stage Prostate Cancer
|
Hartford, Alan |
|
2154: Intensity Modulated Radiotherapy for High Risk Prostate Cancer based on Sentinel Node Optimized Target VolumeDefinition
|
Ganswindt, Ute |
|
2155: Combination of Fast Neutron Irradiation and Permanent Prostate Brachytherapy in Intermediate and High Risk Localized Prostate Cancer
|
Perry, David |
|
2156: Therapeutic Effects of Combination Radiation and Suicide Gene Therapy Using a Chimeric Adenovirus Vector for Bladder Cancer
|
Matsumoto, Kazumasa |
|
2157: Preliminary Toxicity and Quality of Life (QoL) Data From a Randomized Phase III Trial Investigating the Optimal Method of Sequencing Radiation (XRT) and Short Course Total Androgen Blockade (TAB) in Prostate Cancer (PC)
|
Malone, Shawn |
|
2158: Intraoperative Prostate Brachytherapy: Does Real-Time Ultrasound-Based Dosimetry Obviate The Need for Post Implant Dosimetric Analysis? A Retrospective Analysis of 1100 Patients Treated at Kaiser Permanente of Northen California
|
Mahmoudieh, Alireza |
|
2159: Influence of Preimplant International Prostate Symptom Score on Urinary Morbidity Following Prostate Brachytherapy
|
Gutman, Sarah |
|
2160: Does A Delay In Low Dose Rate (LDR) Brachytherapy After Tissue Diagnosis Affect Outcome For Men With Low RiskProstate Cancer?
|
Andrews, Stephen |
|
2161: Pelvic Field Size and Biochemical Failure in the Treatment of Prostate Cancer: A Single Institution Experience
|
Soto, Daniel |
|
2162: Sexual Function After Permanent Prostate Brachytherapy is Not Affected by Penile Bulb Dose
|
Simmons, John |
|
2163: A Case-Control Study of Cluster Size as Predictor of Rectal Bleeding in T1-T2 Prostate Cancer Patients Treated by IMRT
|
Tucker, Susan |
|
2164: Hyperthermia Combined with Radiation in Treatment of Locally Advanced Prostate Cancer is Associated with a Favorable Toxicity Profile
|
Hurwitz, Mark |
|
2165: Rectal Doses Can Be Safely Minimized Without Affecting the Likelihood of Cure After Prostate Brachytherapy
|
Choi, Seungtaek |
|
2166: Trends Analysis in 450 Patients Undergoing Permanent Prostate Brachytherapy Monotherapy with Iodine-125: Improvement in Rectal V100 and Decrease in Standard Deviation of D90
|
Wilson, Torrence |
|
2167: The Impact of MRI Training on Improvement of CT Based Post Implant Dosimetry: A Six Physician Study
|
McLaughlin, Patrick |
|
2168: Can U.S. Prostate Brachytherapy Results be Reproduced in Europe?
|
Khaksar, Sara Jane |
|
2169: Prognostic Significance of Perineural Invasion on Biochemical Progression-Free Survival Following Prostate Brachytherapy
|
Galbreath, Robert |
|
2170: Outcome and Toxicity of Patients with PSA Levels
|
Patel, Rajiv |
|
2171: Shared Decision-Making in Prostate Cancer: Results of a Nationwide Interdisciplinary Consulting Service
|
Bottke, Dirk |
|
2172: Does Hyperinsulinemia in Type-II Diabetes Mellitus Influence Disease Presentation and Long-Term Treatment Outcomes of Localized Prostate Cancer?
|
Nguyen, Khanh |
|
2173: Assessing the Impact of MRI on Determination of Planning Volumes for Conformal Prostate Radiotherapy
|
Joon, Daryl Lim |
|
2174: Pelvic Intensity Modulated Radiation Therapy for High Risk Prostate Cancer
|
Wahab, Sasha |
|
2175: Improving Target (CTV) Delineation for Genitourinary (GU) Malignancies: A Novel Strategy Based on Anatomical and Functional Pelvic Nodal Pathways
|
Teh, Bin |
|
2176: Target Volume Definition for Intensity Modulated Whole Pelvic Radiotherapy (IMWPRT)
|
Staffurth, John |
|
2177: The Role of Neoadjuvant Androgen Suppression Therapy with Salvage Radiation Therapy after Radical Prostatectomy
|
Pai, Howard |
|
2178: Quality of Life Following Prostate Brachytherapy- HRQol Returns to Baseline Within Nine Months
|
Henderson, Alastair |
|
2179: Association of Statin Use with Local Control in Patients Treated with Selective Bladder Preservation for Muscle-Invasive Bladder Cancer
|
Tsai, Henry |
|
2180: Proteomic Approaches to Identify Molecular Alterations in Androgen Independent Prostate Cancer and a Candidate Neuro-Endocrine Peptidase EP24.15
|
Swanson, Todd |
|
2181: Daily Verification of Prostate Motion both with and without a Rectal Balloon (RB) Over the Course of Treatment
|
Canning, Christopher |
|
2182: Cesium-131 Permanent Prostate Brachytherapy: An Initial Report
|
Prestidge, Bradley |
|
